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Recent evidence supports a longstanding hypothesis that chronic stress can inﬂuence tumor growth and progression. It has been
shown that sympathetic neurotransmitters, such as catecholamines and neuropeptides, can aﬀect both cancer cell growth and
tumor vascularization. Depending on neurotransmitter and type of tumor, these eﬀects can be both stimulatory and inhibitory.
Norepinephrine (NE) and epinephrine (E) are potent stimulators of vascularization, acting both by inducing the release of
angiogenic factors from tumor cells and directly on endothelial cell (EC) functions. As a result, activation of the adrenergic system
increases growth of various types of tumors and has been shown to mediate stress-induced augmentation of tumor progression.
Dopamine (DA), on the other hand, interferes with VEGF signaling in endothelial cells, blocks its angiogenic functions and
inhibits tumor growth. Another sympathetic neurotransmitter coreleased with NE, neuropeptide Y (NPY), directly stimulates
angiogenesis. However, proangiogenic actions of NPY can be altered by its direct eﬀect on tumor cell proliferation and survival. In
consequence, NPY can either stimulate or inhibit tumor growth, depending on tumor type. Hence, sympathetic neurotransmitters
are powerful modulators of tumor growth and can become new targets in cancer therapy.
1.Introduction
Stress is an inevitable element of our lives. Stressful events
activate the sympathetic nervous system and hypothalamic-
pituitary-adrenal axis, which lead to the release of biochemi-
cal mediators of stress, such as cortisol, catecholamines, and
neuropeptides [1, 2]. The elevated levels of these factors are
used as clinical markers of stress. These stress mediators
trigger a variety of physiological changes meant to improve
the performance of the organism, such as increasing blood
pressureandheartrateandenhancingtheimmuneresponse.
Thus, a short, acute stress has been shown to exert various
beneﬁcial eﬀects. However, when stress becomes chronic, the
prolongedexposure tothe same stressmediators, whichwere
beneﬁcialinacutestress,oftentriggerspathologicalprocesses
and contributes to the development or exacerbation of
various diseases, including cancer [3].
Chronic stress has been implicated in the stimulation
of tumor development and progression by both clinical
and animal studies [4–6]. Initially, stress-induced suppres-
sion of the immune response was suggested as the major
mechanism of this phenomenon [7]. As opposed to acute
stress, which enhances immunity and has been shown to
increase resistance to cancer, chronic stress impairs immune
responses and in this way facilitates tumor growth [8, 9].
However, there is also growing evidence indicating that
stress mediators, such as glucocorticoids and sympathetic
neurotransmitters,candirectlyaﬀecttumorcellproliferation
a n ds u r v i v a la sw e l la st u m o ra n g i o g e n e s i s .T h ed i r e c te ﬀects
on tumor cells vary signiﬁcantly between diﬀerent stress
mediators and types of tumors [10–13]. In contrast, their
actions on tumor vascularization involve interactions with
common angiogenic factors, such as vascular endothelial
growth factor (VEGF), and seem to be universal between
diﬀerent tumor types [5, 14–16]. Thus, stress mediators and
their receptors can become novel targets in antiangiogenic
tumor therapy. This review will focus on sympathetic
neurotransmittersandtheireﬀectsontumorvascularization.2 Journal of Oncology
2. NorepinephrineandEpinephrine
Norepinephrine(NE)andepinephrine(E)belongtoafamily
of catecholamines and are one of the best characterized
stress neurohormones. NE is released primarily from the
sympathetic nerves, while E is mainly secreted from the
adrenal medulla. As the sympatho-adrenomedullary system
is responsible for the body’s ﬁght-or-ﬂight stress response,
circulating levels of both catecholamines are increased
during stress [17]. NE and E activate the same α and β
adrenoreceptors (AR), which are widely distributed in all
tissues.
Recently, NE and E have been implicated in stress-
induced augmentation of tumor growth and progression.
In an orthotopic model of ovarian carcinoma, the growth-
promoting eﬀect of stress was mimicked by a β-AR agonist,
isoproternol, and blocked by its antagonist, propranolol [5,
6]. Similarly, activation of β-AR resulted in an increase in
metastases in animal models of lung and breast cancer [18,
19]. In all of the above models, the growth-promoting eﬀects
of stress, as well as direct activation of β-ARs, was associated
with a signiﬁcant increase in tumor vascularization, while β-
AR blockers reduced vessel density [5, 6]. Moreover, tumors
derived from stressed animals had elevated levels of VEGF
and other angiogenic factors, and the growth promoting
actions of β-AR activation was reduced by blocking the
VEGFpathway[5].Thus,anincreaseinangiogenesisappears
to be the main mechanism of growth-promoting eﬀects
of NE and E. Indeed, in various cancer cell types, such
as ovarian cancer, colon cancer, melanoma, pharyngeal
carcinoma, and multiple myeloma, activation of β-ARs
present on tumor cells led to a dramatic increase in synthesis
and release of angiogenic factors—VEGF, IL-8, and IL-6
[5, 16, 20–23]. These eﬀects were mediated primarily via a
β-AR-dependent increase in cAMP levels, which resulted in
the activation of protein kinase A (PKA) and Src [5, 22].
Adrenergic stimulation has also been shown to increase the
secretion of metalloproteases, MMP-2 and MMP-9, which
further augment angiogenic and metastatic processes [21].
Interestingly, catecholamine-induced release of angiogenic
factors from tumor cells can be further enhanced by its
secretion from stromal cells, such as β-AR-positive tumor-
associated macrophages [24, 25].
Although the stimulatory eﬀects of NE and E on the
release of angiogenic factors seem to be the major mecha-
nism of their tumor-promoting actions, these neurotrans-
mitters can also exert direct trophic eﬀects on endothelial
cells (ECs) through α-ARs. Phenylepinephrine, a non-
vasoconstrictive α-AR agonist, has been shown to induce
EC proliferation and migration as well as promote capillary
formation. Interestingly, these eﬀects were potentiated by
hypoxia [26]. Since tissue ischemia is known to stimulate
NE release from the sympathetic nerves [27], the direct
angiogenic eﬀect of NE can be signiﬁcantly enhanced in
hypoxic areas of tumors.
Thus far, the results of experimental studies have con-
ﬁrmed that AR agonists exert strong stimulatory eﬀects
on tumor growth and agree that the release of angiogenic
factors is the main mechanism of these actions. These
discoveries open new possibilities of treatment with well-
known drugs, such as antagonists of ARs. Some clinical
dataindicatingdecreasedincidenceofprostatecanceramong
cardiovascular patients treated with β-blockers corroborated
the above ﬁndings [28, 29]. However, it is important to
remember that the indirect, pro-angiogenic eﬀect of AR
agonists mediated by other angiogenic factors depends on
the presence of these receptors on tumor cells, thus it can
be tumor-speciﬁc. Moreover, the angiogenic actions of NE
and E can be further modiﬁed by their direct eﬀect on
tumor cell proliferation and invasiveness, which in turn
may diﬀer among various tumors. In many cancer cell
types, such as colon, ovarian, and prostate, these eﬀects are
stimulatory [11, 12]. However, adrenergic stimulation can
also inhibit proliferation of some tumor cells, as shown in
melanoma and neuroblastoma [30, 31]. In breast cancer, on
the other hand, the reports are contradictory. The adrenergic
agonists seem to increase motility of cancer cells but at the
same time inhibit their proliferation [13, 32]. In agreement
with these data, another clinical study indicated no eﬀect
of treatment with β-blockers on the risk of breast cancer
among cardiovascular patients [33, 34]. Thus, the success
of potential cancer therapy targeting ARs will depend on
the type of tumor, its receptor expression pattern, and
environmentalfactors,suchasstress,whichaugmentNEand
Ee ﬀects.
3.Dopamine
Dopamine (DA) is not only a precursor of NE and E
but is also an important neurotransmitter in the brain
acting via two types of receptors—D1 and D2. In the
periphery, DA is synthesized in mesenteric organs as well
as released from sympathetic neurons and adrenal medulla
[17]. Levels of DA are elevated during stress, but rather
than mediating the ﬁght-or-ﬂight response, as NE and E
do, its role involves coping with stress [35]. DA also seems
to have opposite than NE and E eﬀects on tumor growth.
It has been shown that administration of DA inhibits the
growth of various tumors, such as stomach, breast, and
colon cancers [14, 36]. Consistently, in mice lacking the DA
transporter, which is normally responsible for uptake of this
neurotransmitter,theelevatedDAlevelswereassociatedwith
reduced growth of Lewis lung carcinoma [37]. In gastric
cancer, the endogenous levels of DA were signiﬁcantly lower
than those in surrounding healthy tissue, indicating that the
neurotransmitter acts as an endogenous tumor suppressant
that needs to be inactivated to allow tumor progression
[36].
The main mechanism of these growth-inhibitory actions
of DA involves its direct antiangiogenic eﬀect on ECs. In
all animal models, treatment with DA led to a signiﬁcant
reduction in tumor vascularization [14, 36, 37]. DA has also
beenshowntoblockVEGF-inducedECproliferation,migra-
tion, and vascular permeability. Further studies revealed that
DA, acting through its D2 receptors, enhances endocytosis of
VEGF-R2anddecreasesitsmembraneexpression.Thisactiv-
ity of DA interferes with VEGF signaling by reducing VEGF-
induced phosphorylation of its VEGF-R2 and preventing theJournal of Oncology 3
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Figure 1: Activation of sympathetic neurons results in release of various neurotransmitters—catecholamines and neuropeptides.
Norepinephrine (NE) and Epinephrine (E), belonging to a family of catecholamines, activate their β-adrenoreceptors (ARs) expressed on
tumor cells and stimulate release of angiogenic factors, such as vascular endothelial growth factor (VEGF) and interleukins. Moreover,
NE/E can directly induce endothelial cell (EC) proliferation and migration via their α-AR. Both of these processes lead to an increase
in tumor vascularization. Adrenergic stimulation can also aﬀect proliferation, survival, and invasiveness of cancer cells. This eﬀect may
be stimulatory or inhibitory, depending on tumor type. However, the proangiogenic actions of NE/E prevail over its direct eﬀect on
tumor cells. In consequence, adrenergic activation leads to an increase in tumor growth in most of the investigated tumor types. Another
catecholamine, dopamine (DA), acts on its D2 receptors present on EC and interferes with VEGF signaling. As a result, dopamine reduces
tumor vascularization and inhibits tumor growth. Neuropeptide Y (NPY), coreleased with NE from sympathetic nerves, directly stimulates
EC proliferation and migration via its Y2Rs and increases tumor vascularization. However, NPY can also signiﬁcantly alter the proliferation
and survival of tumor cells. These direct actions of NPY on tumor cells are powerful enough to overcome its angiogenic activities. In
consequence, the net eﬀect of NPY varies in diﬀerent types of tumors.
activation of downstream kinases—FAK and p42/44MAPK
[38, 39].
In addition to its eﬀect on mature ECs, DA has
also been shown to block VEGF signaling in endothelial
progenitor cells (EPCs). As a consequence, DA not only
inhibits trophic functions of VEGF in these cells but also
blocks their recruitment from bone marrow. It has been
shown that DA levels are decreased in the bone marrow
of tumor-bearing mice, which facilitates EPC mobilization
[40]. Since recent data strongly support a role for EPCs
in the tumor vascularization, DA eﬀect on EPC func-
tion may signiﬁcantly contribute to its growth-inhibitory
eﬀect.
T h er o l eo fD Ai ns t r e s s - i n d u c e dc h a n g e si nt u m o r
growth and progression has not been characterized. It seems
that DA is an endogenous inhibitory factor which requires
inactivation for tumor growth, rather than sympathetic
activation. However, in contrast to NE and E acting on
speciﬁc tumors, DA eﬀects appear to be more universal,
inﬂuencing various tumor types, via its direct actions on ECs
andEPCs.Thus,DAreceptoragonistsmaybecomeattractive
antiangiogenic drugs in cancer therapy.
4. Neuropeptide Y
NeuropeptideY(NPY)isa36-amino-acidpeptidecoreleased
with NE from sympathetic nerves. The actions of the peptide
are mediated by multiple receptors-designated Y1–Y5 [41].
NPY is mainly known due to its anxiolytic eﬀect in the brain
and central regulation of food intake. In the periphery, NPY
inhibits the release of NE after sympathetic stimulation and
actsasavasoconstrictor[41].Thereisalsoagrowingnumber
of evidences that NPY is a growth factor for variety of cells.
The peptide has been shown to stimulate proliferation of
vascular smooth muscle cells and neuronal precursors, while
the trophic eﬀect of NPY on ECs revealed its angiogenic
properties [42–47].
The main mechanism of NPY-induced angiogenesis
involves its direct eﬀect on ECs. The peptide stimulates
proliferation and migration of ECs and promotes capillary
tube formation, while in vivo, endogenous NPY facilitates
vascularization of ischemic tissues [43, 46, 47]. These actions
are dependent on endothelial nitric oxide synthase (eNOS)
activation and, partially, on the VEGF pathway [46]. The
angiogenic activities of NPY are mediated mainly by its4 Journal of Oncology
Y2Rs, since NPY-induced angiogenesis is severely impaired
in Y2R −/− mice [48, 49].
Due to its angiogenic properties, NPY has been impli-
cated in various pathological conditions associated with a
deregulation of tissue vascularization, such as retinopathy,
wound healing, atherosclerosis, and obesity [48, 50–52].
Recently, its role in tumor angiogenesis has also been
shown. In malignancies originating from neuroendocrine
tissues, such as neuroblastoma and Ewing’s sarcoma, NPY
released from tumor cells seems to be an essential fac-
tor involved in their vascularization. Antagonists to NPY
receptors blocked the eﬀect of both neuroblastoma and
Ewing’s sarcoma-conditioned media on EC proliferation.
Consequently, treatment with exogenous NPY signiﬁcantly
increasedvascularizationofsubcutaneousxenograftsderived
from both tumor cell types [10].
As in the case of NE and E, the angiogenesis-related
growth-stimulatory actions of NPY are further modiﬁed
by its direct eﬀe c to nt u m o rc e l lg r o w t ha n ds u r v i v a l .
For example, in neuroblastoma, the peptide stimulates
proliferation of tumor cells via the same angiogenic Y2Rs,
thereby further augmenting the growth of neuroblastoma
xenografts. In contrast, in Ewing’s sarcoma, NPY induces
tumor cell apoptosis via Y1 and Y5Rs. As a result, exogenous
NPY inhibits growth of Ewing’s sarcoma xenografts in vivo,
despite increase in their vascularization [10].
Although neuroendocrine tumors, which synthesize and
releaseendogenousNPY,seemthemostsusceptibletotumor
growth regulation by this peptide, NPY and its receptors
have also been implicated in nonneuronal types of tumors.
For example, peptide YY (PYY), which belongs to the same
family of peptides and acts through the same receptors as
NPY, has been shown to inhibit proliferation of breast and
prostate cancer cells via Y4Rs and pancreatic cancer cells
via Y2Rs [53–56]. Thus, these direct eﬀects on tumor cell
proliferation and survival are an important aspect of NPY
actions in tumors and are often potent enough to overcome
its angiogenesis-mediated growth-promoting eﬀect.
Thus far, most of the studies addressing the role of stress
in promoting cancer growth focus on the best known stress
mediators—catecholamines and glucocorticoids. There are
no studies directly linking NPY with stress-induced tumor
growth and progression. However, systemic NPY levels are
also upregulated during stress, particularly those intensive
and prolonged in nature. Moreover, NPY is more stable than
both NE and glucocorticoids. Hence, once stimulated, the
elevated levels of NPY persist for a longer period of time
[57].ThephysiologicalroleofNPYistohelpcopewithstress
due to its central, anxiolytic eﬀects [58, 59]. However, it has
beenshownthatelevatedperipheralcirculatinglevelsofNPY
induced by intensive chronic stress can result in signiﬁcant
deleterious eﬀects, such as enhanced atherosclerosis and
diet-induced obesity, both of which are diseases associated
with intensive tissue growth and upregulated angiogenesis
[52, 60]. Thus, while high levels of NPY in the brain improve
stress coping, chronically elevated levels of the peptide in the
circulation can result in a variety of side eﬀects. Whether
enhanced tumor growth is one of them remains to be
investigated.
5. Summary
As summarized above, the discoveries of recent years
provided a signiﬁcant body of evidence conﬁrming an
importantroleofsympathetic neurotransmittersand,conse-
quently, chronic stress in regulating of tumor vascularization
(Figure 1). This research opens new avenues for developing
novel therapeutics, as well as using already existing and well-
characterized drugs, such as β-blockers and DA receptor
agonists, in new clinical settings. This seems to be partic-
ularly important, since cancer diagnosis per se is usually a
stressfuleventforthepatient.However,carefulconsideration
needs to be given to other actions of stress mediators,
such as cancer-speciﬁc eﬀects on tumor cells themselves,
as well as changes in immune system, which can indirectly
aﬀect tumor development and progression. Finally, since
patterns of neuro-hormonal activation vary with diﬀerent
t y p e so fs t r e s s[ 17], tumor exposure to particular stress
mediators would vary, too. Thus, potential therapeutic value
ofmodifyingparticularstresspathwaysmaybedependenton
a variety of factors.
Acknowledgments
This work was supported by Grant no. 1R01CA123211-
01 from the National Institutes of Health, grant no.
CA093337 from the Department of Defense, and funding
from Children’s Cancer Foundation (Baltimore, MD) to
Joanna Kitlinska.
References
[ 1 ]G .P .C h r o u s o sa n dP .W .G o l d ,“ T h ec o n c e p t so fs t r e s sa n d
stress system disorders: overview of physical and behavioral
homeostasis,” Journal of the American Medical Association, vol.
267, no. 9, pp. 1244–1252, 1992.
[2] T. E. Seeman, B. H. Singer, J. W. Rowe, R. I. Horwitz, and
B. S. McEwen, “Price of adaptation—allostatic load and its
health consequences: MacArthur studies of successful aging,”
Archives of Internal Medicine, vol. 157, no. 19, pp. 2259–2268,
1997.
[3] B. S. McEwen and E. Stellar, “Stress and the individual.
Mechanisms leading to disease,” Archives of Internal Medicine,
vol. 153, no. 18, pp. 2093–2101, 1993.
[ 4 ]M .H .A n t o n i ,S .K .L u t g e n d o r f ,S .W .C o l e ,e ta l . ,“ T h e
inﬂuence of bio-behavioural factors on tumour biology:
pathways and mechanisms,” Nature Reviews Cancer, vol. 6, no.
3, pp. 240–248, 2006.
[5] P. H. Thaker, L. Y. Han, A. A. Kamat, et al., “Chronic stress
promotestumorgrowthandangiogenesisinamousemodelof
ovarian carcinoma,” Nature Medicine, vol. 12, no. 8, pp. 939–
944, 2006.
[6] J.-W. Lee, M. M. K. Shahzad, Y. G. Lin, et al., “Surgical
stress promotes tumor growth in ovarian carcinoma,” Clinical
Cancer Research, vol. 15, no. 8, pp. 2695–2702, 2009.
[7] J.P.GodboutandR.Glaser,“Stress-inducedimmunedysregu-
lation: implications for wound healing, infectious disease and
cancer,” Journal of Neuroimmune Pharmacology, vol. 1, no. 4,
pp. 421–427, 2006.Journal of Oncology 5
[8] F. S. Dhabhar, A. N. Saul, C. Daugherty, T. H. Holmes, D.
M. Bouley, and T. M. Oberyszyn, “Short-term stress enhances
cellular immunity and increases early resistance to squamous
cell carcinoma,” Brain, Behavior, and Immunity,v o l .2 4 ,n o .1 ,
pp. 127–137, 2010.
[9] F. S. Dhabhar, “Enhancing versus suppressive eﬀects of stress
onimmunefunction:implicationsforimmunoprotectionand
immunopathology,” NeuroImmunoModulation, vol. 16, no. 5,
pp. 300–317, 2009.
[ 1 0 ]J .K i t l i n s k a ,K .A b e ,L .K u o ,e ta l . ,“ D i ﬀerential eﬀects of
neuropeptide Y on the growth and vascularization of neural
crest-derived tumors,” Cancer Research,v o l .6 5 ,n o .5 ,p p .
1719–1728, 2005.
[11] D. Palm, K. Lang, B. Niggemann, et al., “The norepinephrine-
driven metastasis development of PC-3 human prostate
cancer cells in BALB/c nude mice is inhibited by β-blockers,”
International Journal of Cancer, vol. 118, no. 11, pp. 2744–
2749, 2006.
[12] A. K. Sood, R. Bhatty, A. A. Kamat, et al., “Stress hormone-
mediated invasion of ovarian cancer cells,” Clinical Cancer
Research, vol. 12, no. 2, pp. 369–375, 2006.
[13] A. E. Carie and S. M. Sebti, “A chemical biology approach
identiﬁes a β-2 adrenergic receptor agonist that causes human
tumor regression by blocking the Raf-1/Mek-1/Erk1/2 path-
way,” Oncogene, vol. 26, no. 26, pp. 3777–3788, 2007.
[ 1 4 ]C .S a r k a r ,D .C h a k r o b o r t y ,U .R .C h o w d h u r y ,P .S .D a s g u p t a ,
and S. Basu, “Dopamine increases the eﬃcacy of anticancer
drugs in breast and colon cancer preclinical models,” Clinical
Cancer Research, vol. 14, no. 8, pp. 2502–2510, 2008.
[15] D. Chakroborty, C. Sarkar, B. Basu, P. S. Dasgupta, and S.
Basu, “Catecholamines regulate tumor angiogenesis,” Cancer
Research, vol. 69, no. 9, pp. 3727–3730, 2009.
[16] E. V. Yang, S.-J. Kim, E. L. Donovan, et al., “Norepinephrine
upregulates VEGF, IL-8, and IL-6 expression in human
melanoma tumor cell lines: implications for stress-related
enhancement of tumor progression,” Brain, Behavior, and
Immunity, vol. 23, no. 2, pp. 267–275, 2009.
[17] D. S. Goldstein, “Catecholamines and stress,” Endocrine Regu-
lations, vol. 37, no. 2, pp. 69–80, 2003.
[18] S. Ben-Eliyahu, R. Yirmiya, J. C. Liebeskind, A. N. Taylor, and
R. P. Gale, “Stress increases metastatic spread of a mammary
tumor in rats: evidence for mediation by the immune system,”
Brain, Behavior, and Immunity, vol. 5, no. 2, pp. 193–205,
1991.
[19] R. Melamed, E. Rosenne, K. Shakhar, Y. Schwartz, N. Abu-
darham, and S. Ben-Eliyahu, “Marginating pulmonary-NK
activity and resistance to experimental tumor metastasis:
suppression by surgery and the prophylactic use of a β-
adrenergicantagonistandaprostaglandinsynthesisinhibitor,”
Brain, Behavior, and Immunity, vol. 19, no. 2, pp. 114–126,
2005.
[20] Z. R. Yang and K.-C. Chou, “Bio-support vector machines for
computational proteomics,” Bioinformatics,v o l .2 0 ,n o .5 ,p p .
735–741, 2004.
[21] E. V. Yang, A. K. Sood, M. Chen, et al., “Norepinephrine
up-regulates the expression of vascular endothelial growth
factor, matrix metalloproteinase (MMP)-2, and MMP-9 in
nasopharyngeal carcinoma tumor cells,” Cancer Research, vol.
66, no. 21, pp. 10357–10364, 2006.
[22] M. B. Nilsson, G. Armaiz-Pena, R. Takahashi, et al., “Stress
hormonesregulateinterleukin-6expressionbyhumanovarian
carcinoma cells through a Src-dependent mechanism,” The
Journal of Biological Chemistry, vol. 282, no. 41, pp. 29919–
29926, 2007.
[23] H. P. S. Wong, L. Yu, E. K. Y. Lam, E. K. K. Tai, W. K. K. Wu,
and C.-H. Cho, “Nicotine promotes colon tumor growth and
angiogenesis through β-adrenergic activation,” Toxicological
Sciences, vol. 97, no. 2, pp. 279–287, 2007.
[24] J. W. Pollard, “Tumour-educated macrophages promote
tumour progression and metastasis,” Nature Reviews Cancer,
vol. 4, no. 1, pp. 71–78, 2004.
[25] S. K. Lutgendorf, D. M. Lamkin, N. B. Jennings, et al., “Biobe-
havioral inﬂuences on matrix metalloproteinase expression in
ovarian carcinoma,” Clinical Cancer Research, vol. 14, no. 21,
pp. 6839–6846, 2008.
[26] M.C.Vinci,L.Bellik,S.Filippi,etal.,“Trophiceﬀectsinduced
by α1D-adrenoceptors on endothelial cells are potentiated by
hypoxia,” American Journal of Physiology, vol. 293, no. 4, pp.
H2140–H2147, 2007.
[27] V. Borovsky, M. Herman, G. Dunphy, et al., “CO2 asphyxia
increases plasma norepinephrine in rats via sympathetic
nerves,” American Journal of Physiology, vol. 274, no. 1, part
2, pp. R19–R22, 1998.
[28] L. Perron, I. Bairati, F. Harel, and F. Meyer, “Antihypertensive
drug use and the risk of prostate cancer (Canada),” Cancer
Causes and Control, vol. 15, no. 6, pp. 535–541, 2004.
[29] C. Rodriguez, E. J. Jacobs, A. Deka, et al., “Use of blood-
pressure-lowering medication and risk of prostate cancer in
the Cancer Prevention Study II Nutrition Cohort,” Cancer
Causes and Control, vol. 20, no. 5, pp. 671–679, 2009.
[30] C. Piﬂ, J. Zezula, A. Spittler, et al., “Antiproliferative action
of dopamine and norepinephrine in neuroblastoma cells
expressing the human dopamine transporter,” The FASEB
Journal, vol. 15, no. 9, pp. 1607–1609, 2001.
[31] A. C. Scarparo, D. H. Sumida, M. T. C. C. Patr˜ ao, M.
C. W. Avellar, M. A. Visconti, and A. M. D. L. Castrucci,
“Catecholamine eﬀects on human melanoma cells evoked by
α1-adrenoceptors,” Archives of Dermatological Research, vol.
296, no. 3, pp. 112–119, 2004.
[ 3 2 ]T .L .D r e l lI V ,J .J o s e p h ,K .L a n g ,B .N i g g e m a n n ,K .S .
Zaenker, and F. Entschladen, “Eﬀects of neurotransmitters on
the chemokinesis and chemotaxis of MDA-MB-468 human
breast carcinoma cells,” Breast Cancer Research and Treatment,
vol. 80, no. 1, pp. 63–70, 2003.
[33] C. R. Meier, L. E. Derby, S. S. Jick, and H. Jick, “Angiotensin-
converting enzyme inhibitors, calcium channel blockers, and
breastcancer,”ArchivesofInternalMedicine,vol.160,no.3,pp.
349–353, 2000.
[ 3 4 ]C .I .L i ,K .E .M a l o n e ,N .S .W e i s s ,D .M .B o u d r e a u ,K .L .
Cushing-Haugen, and J. R. Daling, “Relation between use of
antihypertensive medications and risk of breast carcinoma
among women ages 65–79 years,” Cancer,v o l .9 8 ,n o .7 ,p p .
1504–1513, 2003.
[35] S. R. Snider and O. Kuchel, “Dopamine: an important
neurohormone of the sympathoadrenal system. Signiﬁcance
of increased peripheral dopamine release for the human stress
response and hypertension,” Endocrine Reviews, vol. 4, no. 3,
pp. 291–309, 1983.
[36] D. Chakroborty, C. Sarkar, R. B. Mitra, S. Banerjee, P. S.
Dasgupta, and S. Basu, “Depleted dopamine in gastric cancer
tissues: dopamine treatment retards growth of gastric cancer
by inhibiting angiogenesis,” Clinical Cancer Research, vol. 10,
no. 13, pp. 4349–4356, 2004.6 Journal of Oncology
[37] M. Asada, S. Ebihara, Y. Numachi, et al., “Reduced tumor
growth in a mouse model of schizophrenia, lacking the
dopamine transporter,” International Journal of Cancer, vol.
123, no. 3, pp. 511–518, 2008.
[38] S. Basu, J. A. Nagy, S. Pal, et al., “The neurotransmitter
dopamine inhibits angiogenesis induced by vascular per-
meability factor/vascular endothelial growth factor,” Nature
Medicine, vol. 7, no. 5, pp. 569–574, 2001.
[ 3 9 ]C .S a r k a r ,D .C h a k r o b o r t y ,R .B .M i t r a ,S .B a n e r j e e ,P .S .
Dasgupta, and S. Basu, “Dopamine in vivo inhibits VEGF-
induced phosphorylation of VEGFR-2, MAPK, and focal
adhesion kinase in endothelial cells,” American Journal of
Physiology, vol. 287, no. 4, pp. H1554–H1560, 2004.
[40] D. Chakroborty, U. R. Chowdhury, C. Sarkar, R. Baral, P.
S. Dasgupta, and S. Basu, “Dopamine regulates endothelial
progenitor cell mobilization from mouse bone marrow in
tumor vascularization,” Journal of Clinical Investigation, vol.
118, no. 4, pp. 1380–1389, 2008.
[41] W. F. Colmers and C. Wahlestedt, The Biology of Neuropeptide
Y and Related Peptides, Humana Press, Totowa, NJ, USA, 1993.
[42] Z. Zukowska-Grojec, P. Pruszczyk, C. Colton, et al., “Mito-
genic eﬀect of neuropeptide Y in rat vascular smooth muscle
cells,” Peptides, vol. 14, no. 2, pp. 263–268, 1993.
[43] Z. Zukowska-Grojec, E. Karwatowska-Prokopczuk, W. Rose,
et al., “Neuropeptide Y a novel angiogenic factor from the
sympathetic nerves and endothelium,” Circulation Research,
vol. 83, no. 2, pp. 187–195, 1998.
[44] D.E.Hansel,B.A.Eipper,andG.V.Ronnett,“NeuropeptideY
functions as a neuroproliferative factor,” Nature, vol. 410, no.
6831, pp. 940–944, 2001.
[45] J. Pons, J. Kitlinska, H. Ji, et al., “Bimodal mitogenic action of
neuropeptide Y in vascular smooth muscle cells: dimerization
of the receptors?” Molecular Biology of the Cell, vol. 13,
supplement, article 80a, 2002.
[46] E. W. Lee, M. Michalkiewicz, J. Kitlinska, et al., “Neuropeptide
Y induces ischemic angiogenesis and restores function of
ischemicskeletalmuscles,”JournalofClinicalInvestigation,vol.
111, no. 12, pp. 1853–1862, 2003.
[47] S. Movafagh, J. P. Hobson, S. Spiegel, H. K. Kleinman, and Z.
Zukowska, “Neuropeptide Y induces migration, proliferation,
and tube formation of endothelial cells bimodally via Y1, Y2,
and Y5 receptors,” The FASEB Journal, vol. 20, no. 11, pp.
1924–1926, 2006.
[48] A. J. Ekstrand, R. Cao, M. Bj¨ orndahl, et al., “Deletion of
neuropeptide Y (NPY)2 receptor in mice results in blockage
of NPY-induced angiogenesis and delayed wound healing,”
Proceedings of the National Academy of Sciences of the United
States of America, vol. 100, no. 10, pp. 6033–6038, 2003.
[49] E. W. Lee, D. S. Grant, S. Movafagh, and Z. Zukowska,
“Impaired angiogenesis in neuropeptide Y (NPY)-Y2 receptor
knockout mice,” Peptides, vol. 24, no. 1, pp. 99–106, 2003.
[50] L. Li, E. W. Lee, H. Ji, and Z. Zukowska, “Neuropeptide
Y-induced acceleration of postangioplasty occlusion of rat
carotid artery,” Arteriosclerosis, Thrombosis, and Vascular Biol-
ogy, vol. 23, no. 7, pp. 1204–1210, 2003.
[51] M. Koulu, S. Movafagh, J. Tuohimaa, et al., “Neuropeptide
Y and Y2-receptor are involved in development of dia-
betic retinopathy and retinal neovascularization,” Annals of
Medicine, vol. 36, no. 3, pp. 232–240, 2004.
[52] L. E. Kuo, J. B. Kitlinska, J. U. Tilan, et al., “Neuropeptide Y
acts directly in the periphery on fat tissue and mediates stress-
induced obesity and metabolic syndrome,” Nature Medicine,
vol. 13, no. 7, pp. 803–811, 2007.
[53] C. D. Liu, A. Balasubramaniam, R. E. Saxton, M. Paiva, and D.
W. McFadden, “Human pancreatic cancer growth is inhibited
by peptide YY and BIM-43004-1,” Journal of Surgical Research,
vol. 58, no. 6, pp. 707–712, 1995.
[54] K. R. Grise, A. J. Rongione, E. C. Laird, and D. W. McFadden,
“Peptide YY inhibits growth of human breast cancer in vitro
and in vivo,” Journal of Surgical Research, vol. 82, no. 2, pp.
151–155, 1999.
[55] T. Heisler, S. Towﬁgh, N. Simon, and D. W. McFadden,
“Peptide YY and vitamin E inhibit hormone-sensitive and -
insensitivebreastcancercells,”JournalofSurgicalResearch,vol.
91, no. 1, pp. 9–14, 2000.
[56] A. Yu, P. Somasundar, A. Balsubramaniam, A. T. Rose, L.
Vona-Davis, and D. W. McFadden, “Vitamin E and the
Y4 agonist BA-129 decrease prostate cancer growth and
production of vascular endothelial growth factor,” Journal of
Surgical Research, vol. 105, no. 1, pp. 65–68, 2002.
[57] Z. Zukowska-Grojec, “Neuropeptide Y. A novel sympathetic
stress hormone and more,” Annals of the New York Academy of
Sciences, vol. 771, pp. 219–233, 1995.
[58] A. Thorsell, M. Michalkiewicz, Y. Dumont, et al., “Behavioral
insensitivity to restraint stress, absent fear suppression of
behavior and impaired spatial learning in transgenic rats with
hippocampal neuropeptide Y overexpression,” Proceedings of
the National Academy of Sciences of the United States of
America, vol. 97, no. 23, pp. 12852–12857, 2000.
[59] C. C. Carvajal, F. Vercauteren, Y. Dumont, M. Michalkiewicz,
and R. Quirion, “Aged neuropeptide Y transgenic rats are
resistant to acute stress but maintain spatial and non-spatial
learning,” Behavioural Brain Research, vol. 153, no. 2, pp. 471–
480, 2004.
[60] L. Li, A.-C. J¨ onsson-Rylander, K. Abe, and Z. Zukowska,
“Chronicstressinducesrapidocclusionofangioplasty-injured
rat carotid artery by activating neuropeptide Y and its Y1
receptors,” Arteriosclerosis, Thrombosis, and Vascular Biology,
vol. 25, no. 10, pp. 2075–2080, 2005.